| CG5567 |
Drosophila melanogaster |
|
CG5567 is differentially expressed in 10 experiments [13 up/11 dn]: 9 organism parts: whole_organism [0 up/2 dn], Malpighian tubule [2 up/0 dn], ...; 2 disease states: Drosophila C virus [0 up/1 dn], reference [1 up/0 dn], 2 compound treatments, 1 developmental stages, 4 genotypes and 1 other conditions. |
| CG11780, CG5567, Dmel_CG11780, beta4GalT7, beta4GalT7-RA, beta-4GalT7 |
|
Pgp (Mus musculus)
Pgp (Rattus norvegicus)
K09H11.7 (Caenorhabditis elegans)
PGP (Homo sapiens)
pgp (Danio rerio)
PHO13 (Saccharomyces cerevisiae)
K02D10.1 (Caenorhabditis elegans)
PLPP_RAT (Rattus norvegicus)
Pdxp (Mus musculus)
(Compare orthologs)
|
|
|
| Metazoa galactosyltransferase |
|
|
| Golgi apparatus, chondroitin sulfate biosynthetic process, heparan sulfate proteoglycan biosynthetic process, xylosylprotein 4-beta-galactosyltransferase activity |
|
|
|
Q8I6J0
Q8T3P3
Q9VBZ9
|
|
|
|
FBgn0036760
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Whole_organism
|
Organism part |
|
|
Malpighian tubule
|
Organism part |
|
|
Accessory gland
|
Organism part |
|
|
Ada2aΔ189
|
Genotype |
|
|
Subcutaneous fat-body
|
Organism part |
|
|
Midgut
|
Organism part |
|
|
Control
|
Compound treatment |
|
|
Phenobarbital
|
Compound treatment |
|
|
W1118
|
Genotype |
|
|
MSL1
|
RNAi |
|
|
MSL3
|
RNAi |
|
|
MSL1_GFP
|
RNAi |
|
|
FRT79D, ebony / Gcn5[E333st]
|
Genotype |
|
|
Hindgut
|
Organism part |
|
|
Brain
|
Organism part |
|
|
Drosophila C virus
|
Disease state |
|
|
Reference
|
Disease state |
|
|
MOF
|
RNAi |
|
|
Prepupae
|
Developmental stage |
|
|
Testis
|
Organism part |
|
|
Ovary
|
Organism part |
|
|
Nurf301-A/Nurf301-B/Nurf301-C ...
|
Genotype |
|
|
|
|
|
Processing time: 0.149 secs.